NLRP3 and cardiovascular disorder: In this regard, several clinical trials are currently evaluating immunomodulatory strategies in cardiovascular disease, including IL-6 blockade with ziltivekimab, selective NLRP3 inhibitors such as dapansutrile, and established anti-inflammatory agents such as colchicine and canakinumab [101,102,103].